Ovid Therapeutics Inc
Ovid Therapeutics Inc (OVID) Covered Calls
As of September 25, 2026, OVID has 1 covered call opportunities in the coming three months. Return ranges from 180.7 to 180.7% until expiration. Annualized return ranges from 314.0 to 314.0%. The nearest expiration is April 16, 2027. Maximum potential profit is $486.
Read more
Running OVID covered calls helps you generate consistent income from Ovid Therapeutics Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Ovid Therapeutics Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best OVID covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if OVID stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling OVID covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Ovid Therapeutics Inc covered call is worth writing.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder.
The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Income-focused investors, long-term OVID holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling OVID covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Ovid Therapeutics Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile42.86% Neutral
- Market cap (M$)469
- 52 weeks high-22.58%
- 52 weeks low103.39%
- Analyst recommendationStrong Buy
1.00 - Target price$6.00
150.00% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-11
- P/E—
- Future P/E—
- EPS (ttm)-0.25
- EPS growth next 5 years-26.75%
As of September 25, 2026
| 2027-04-16 | 210 | 7.50 | 178.81 | 0.05 | 0.70 | 486.00 | 180.67 | 314.02 | -1.86 | +0.33 | 101 | 0.65 |
As of September 25, 2026
Sell covered calls with the data behind you
Find the best OVID covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→